Large increase in bloodstream infections with carbapenem-resistant Acinetobacter species during the first 2 years of the COVID-19 pandemic, EU/EEA, 2020 and 2021.

Authors :: Kinross P
Gagliotti C
Merk H
Plachouras D
Monnet DL
Högberg LD
Source :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2022 Nov; Vol. 27 (46).
Publication Year :: 2022
Abstract: Recent data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) show a large increase of +57% in Acinetobacter species bloodstream infections in the European Union and European Economic Area in the first years of the COVID-19 pandemic (2020-2021) compared with 2018-2019. Most were resistant to carbapenems, from intensive care units, and in countries with ≥ 50% carbapenem resistance in Acinetobacter spp. in 2018-2019. This highlights the requirement for reinforced Acinetobacter preparedness and infection prevention and control in Europe.

Subjects :: Humans
Drug Resistance, Bacterial
Pandemics
Anti-Bacterial Agents pharmacology
Anti-Bacterial Agents therapeutic use
Carbapenems pharmacology
Carbapenems therapeutic use
COVID-19
Acinetobacter
Sepsis drug therapy

Language :: English
ISSN :: 1560-7917
Volume :: 27
Issue :: 46
Database :: MEDLINE
Journal :: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Publication Type :: Academic Journal
Accession number :: 36398574
Full Text :: https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200845

Full Text Access

Tools